BNTXBioNTech SE

Nasdaq biontech.de


$ 91.57 $ -0.39 (-0.42 %)    

Friday, 10-May-2024 15:58:47 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 91.67
$ 92.70
$ 91.66 x 200
$ 0.00 x 0
$ 91.55 - $ 93.33
$ 85.21 - $ 125.83
389,880
na
21.79M
$ 0.08
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 hc-wainwright--co-maintains-buy-on-biontech-raises-price-target-to-113

HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $1...

 td-cowen-maintains-hold-on-biontech-raises-price-target-to-98

TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:BNTX) with a Hold and raises the price target from $95 to $98.

 bmo-capital-maintains-outperform-on-biontech-lowers-price-target-to-122

BMO Capital analyst Etzer Darout maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $123 to...

 whats-going-with-biontech-stock-on-monday

BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by inn...

 wall-street-looks-to-extend-rally-amid-caution-over-fed-speeches-more-earnings-why-this-analyst-thinks-bull-market-is-still-quite-young

U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports cont...

 biontech-reaffirms-2024-revenue-guidance-of-25b-31b

Planned 2024 Financial Year Expenses and Capex R&D expenses: €2.4B-€2.6B SG&A expenses: €700M-€800M Capital expend...

 will-earnings-cheer-continue-this-week-all-eyes-on-disney-palantir-robinhood-while-reddit-gears-up-for-debut-quarterly-report

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

 gsk-sees-strong-demand-for-vaccines-and-asthma-drugs-raises-annual-outlook

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Sp...

 covid-19-patent-dispute-sorted-acuitas-therapeutics-and-curevac-reach-settlement-in-patent-battle

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfi...

 whats-going-on-with-pfizer-stock-on-thursday

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying hig...

 moderna-faces-pfizer-biontech-in-london-patent-battle-over-covid-19-vaccines-in-legal-showdown

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmace...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-107-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $107 price target.

 reported-sunday-biontech-three-year-phase-1-follow-up-data-for-mrna-based-individualized-immunotherapy-candidate-shows-persistence-of-immune-response-and-delayed-tumor-recurrence-in-some-patients-with-resected-pancreatic-cancer

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate auto...

 curevac-gsk-partner-release-data-on-influenza-vaccine-study

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen c...

 ubs-maintains-neutral-on-biontech-lowers-price-target-to-101

UBS analyst Eliana Merle maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $110 to $101.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION